T
Teena Vagrhese
Researcher at Millennium Pharmaceuticals
Publications - 2
Citations - 4
Teena Vagrhese is an academic researcher from Millennium Pharmaceuticals. The author has contributed to research in topics: Raf Kinase Inhibitor & Cancer. The author has an hindex of 1, co-authored 2 publications receiving 4 citations.
Papers
More filters
Proceedings ArticleDOI
Abstract C146: Combination treatment with the investigational RAF kinase inhibitor MLN2480 and the investigational MEK kinase inhibitor TAK-733 inhibits the growth of BRAF mutant and RAS mutant preclinical models of melanoma and CRC.
Elizabeth Grace Carideo Cunniff,Julie Zhang,Jouhara Chouitar,Jerome T. Mettetal,Kazuhide Nakamura,Takeo Arita,Akito Nakamura,Masanori Okaniwa,Tomoyasu Ishikawa,Sei Yoshida,Robyn Fabrey,Patrick Vincent,Kurt Eng,Khristofer Garcia,Deanna Borelli,Teena Vagrhese,Steve Stroud,Saurabh Menon,Mike Kuranda,Katherine M. Galvin +19 more
TL;DR: The combination of MLN2480 with the MEK inhibitor TAK-733 represents an additional strategy for clinical research within these tumor types and demonstrates synergistic activity in cell proliferation assays.
Journal ArticleDOI
Use of combination treatment with the investigational RAF kinase inhibitor MLN2480 and the investigational MEK kinase inhibitor TAK-733 on the growth of BRAF-mutant and RAS-mutant preclinical models of melanoma and CRC.
Elizabeth Grace Carideo Cunniff,Julie Zhang,Jouhara Chouitar,Jerome T. Mettetal,Kazuhide Nakamura,Takeo Arita,Akito Nakamura,Masanori Okaniwa,Tomoyasu Ishikawa,Sei Yoshida,Robyn Fabrey,Patrick Vincent,Kurt Eng,Khristofer Garcia,Deanna Borrelli,Teena Vagrhese,Steve Stroud,Saurabh Menon,Mike Kuranda,Katherine M. Galvin +19 more
TL;DR: In this article, RAS mutant melanoma and colorectal cancer represent areas of significant unmet medical need and MLN2480 is an investigational class II RAF kinase inhibitor.